8-Azaadenosine
Based on 5 publication(s) in Google Scholar
8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.94%
- CAS. Nr.: 10299-44-2
- Formel: C9H12N6O4
- Molecular Weight:268.23
-
Speicherung:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Endocrinology Compound Library
HY-L047
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) 8-Azaadenosine
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEp-2 | ED50 |
0.8 μM
Compound: 4, 8-azaadenosine
|
Cytotoxicity against human Hep2 cells assessed as growth inhibition
Cytotoxicity against human Hep2 cells assessed as growth inhibition
|
[PMID: 556773] |
| HEp-2 | IC50 |
<0.02 μM
Compound: 1
|
Cytotoxicity against H.Ep cells in the presence of 0.1 ug/mL pentostatin.
Cytotoxicity against H.Ep cells in the presence of 0.1 ug/mL pentostatin.
|
[PMID: 6620307] |
| HEp-2 | IC50 |
0.7 μM
Compound: 1
|
Cytotoxicity against H.Ep cells
Cytotoxicity against H.Ep cells
|
[PMID: 6620307] |
8-Azaadenosine targets ADAR (adenosine deaminases acting on double-stranded RNA) activity only and does not affect ADAR1 mRNA levels[1][2].
8-Azaadenosine (10-25 nM) restores let-7 miRNA biogenesis commensurate with a reduction in ADAR1 expression, RNA editing activity and LIN28B expression in JAK2/BCR-ABL1 transduced progenitors after two weeks in stromal co-culture[1].
8-Azaadenosine (10, 100 nM) shows no effect on BCR-ABL and JAK2 signaling, as demonstrated by qRT-PCR analysis and p-CRKL and p-STAT5a Western blot analysis[1].
8-Azaadenosine (0.1, 0.5, 1, 2 μM; 5 days) decreases cell viability/proliferation in a dose-dependent manner in TPC1 and Cal62 cells[2].
8-Azaadenosine (1, 2 μM; 16 hours) impedes invasion and migration of TPC1 and Cal62 cells[2].
8-Azaadenosine (1, 2 μM) inhibits the editing activity in TPC1 and Cal62 cells. By contrast, ADAR1 mRNA levels remains stable in both cells lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 10299-44-2
-
Appearance Solid
-
Molecular Weight 268.23
-
Formel C9H12N6O4
-
Color White to off-white
-
SMILES
NC1=NC=NC2=C1N=NN2[C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
Coronavirus S protein alters dsRNA accumulation and stress granule formation through regulation of ADAR1-p150 expression. [Abstract]2024 Nov 27;52(21):13174-13191. PMID: 39445805 -
Acta Pharm Sin B
ADAR1 regulates vascular remodeling in hypoxic pulmonary hypertension through N 1-methyladenosine modification of circCDK17. [Abstract]2023 Dec;13(12):4840-4855. PMID: 38045055
8-Azaadenosine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Dec;13(12):4840-4855. [Abstract]
Schematic illustration showing the drug treatment protocol. 8-Azaadenosine (2 mg/kg) was injected intraperitoneally every four days for 28 days for hypoxia or 35 days for SuHx (hypoxia combined with Su5416) PH models.
8-Azaadenosine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Dec;13(12):4840-4855. [Abstract]
Hemodynamic analysis showing the therapeutic effects of 8-Azaadenosine (2 mg/kg, every four days for 28 days, ip) on Right ventricular systolic pressure (RVSP), and right ventricle (RV)/left ventricle (LV)+S weight ratio, n = 6.
8-Azaadenosine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Dec;13(12):4840-4855. [Abstract]
Hematoxylin-eosin staining (HE) staining showing that 8-Azaadenosine significantly attenuated the increased median wall thickness of pulmonary vascular vessels caused by either hypoxia alone or SuHx, n = 6. NOR, normoxia; HYP, hypoxia, ns, no significance; Statistical analysis was performed with two-way ANOVA followed by Dunnett's test.
8-Azaadenosine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Dec;13(12):4840-4855. [Abstract]
CCK8 analysis showing the concentration-dependent effect of 8-Azaadenosine (0.01-0.1 μmol/L) on hypoxia-stimulated cell viability, n = 6.
8-Azaadenosine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Dec;13(12):4840-4855. [Abstract]
EdU staining assay showing that 8Aza abolished hypoxia-induced cell proliferation, n = 6. NOR, normoxia; HYP, hypoxia; NC, negative control; SI, siRNA of ADAR1; OE, ADAR1 overexpression plasmid.
-
Proc Natl Acad Sci U S A
Stress granule-mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging. [Abstract]2025 Aug 19;122(33):e2514837122. PMID: 40811463 -
J Cancer
Targeting ADAR1 suppresses progression and peritoneal metastasis of gastric cancer through Wnt / β-catenin pathway. [Abstract]2021 Oct 28;12(24):7334-7348. PMID: 35003354 -
Lösungsmittel & Löslichkeit
DMSO : 250 mg/mL (932.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 3.33 mg/mL (12.41 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Maria Anna Zipeto, et al. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell. 2016 Aug 4;19(2):177-191. [Content Brief]
[2]. Julia Ramírez-Moya, et al. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. Oncogene. 2020 Apr;39(18):3738-3753. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.7281 mL | 18.6407 mL | 37.2814 mL | 93.2036 mL |
| 5 mM | 0.7456 mL | 3.7281 mL | 7.4563 mL | 18.6407 mL | |
| 10 mM | 0.3728 mL | 1.8641 mL | 3.7281 mL | 9.3204 mL | |
| DMSO | 15 mM | 0.2485 mL | 1.2427 mL | 2.4854 mL | 6.2136 mL |
| 20 mM | 0.1864 mL | 0.9320 mL | 1.8641 mL | 4.6602 mL | |
| 25 mM | 0.1491 mL | 0.7456 mL | 1.4913 mL | 3.7281 mL | |
| 30 mM | 0.1243 mL | 0.6214 mL | 1.2427 mL | 3.1068 mL | |
| 40 mM | 0.0932 mL | 0.4660 mL | 0.9320 mL | 2.3301 mL | |
| 50 mM | 0.0746 mL | 0.3728 mL | 0.7456 mL | 1.8641 mL | |
| 60 mM | 0.0621 mL | 0.3107 mL | 0.6214 mL | 1.5534 mL | |
| 80 mM | 0.0466 mL | 0.2330 mL | 0.4660 mL | 1.1650 mL | |
| 100 mM | 0.0373 mL | 0.1864 mL | 0.3728 mL | 0.9320 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
8-Azaadenosine Related Classifications
HY-115686 Related Classifications
Powered by Bioz